Join us for a robust discussion on technology advancements, trends, and strategies regarding the future of telematics. The industry leaders on our panel will provide their unique perspectives and take questions on vehicle connectivity.
Our speakers will explore:
- Issues surrounding lag time between innovation and mass production
- Consumer-driven demands on OEMs for more infotainment-related technology
- Fully connected “smart” cars and multi-modal synergies as a major target of future expansion for manufacturers
- Autonomous technology and its potential to address driver-distraction concerns
We hope you will attend our complimentary breakfast program before heading over to Industry Day at the Detroit Auto Show.
Speakers
- Henry Bzeih, Head of Telematics & Infotainment, Kia Motors America
- Nigel Francis, Vice President, Corporate Planning, American Axle & Manufacturing, Inc.
- Chanley Howell, Partner, Foley & Lardner LLP
Introductory Remarks
- Jay O. Rothman, Chairman and CEO, Foley & Lardner LLP
People
Related Insights
12 March 2025
Health Care Law Today
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA’s Declaration that Tirzepatide Shortage is Resolved; Plaintiff OFA Appeals
On March 5, 2025, one U.S. District Court ruled unequivocally in the Food & Drug Administration’s (FDA) favor in the case, Outsourcing Facilities Ass’n, et. al. v. U.S. Food and Drug Admin., et. al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15 (N.D. Tex. Mar. 5, 2025), denying plaintiffs’ motion for (1) a preliminary injunction (PI) prohibiting the FDA from taking action against Outsourcing Facilities Association (OFA) members and FarmaKeio based on their compounding of the drug ingredient tirzepatide pending final judgment in the case and (2) a stay pending conclusion of the review proceedings in response to the FDA’s declaration that the shortage of the diabetes and weight-loss tirzepatide products has been resolved.
12 March 2025
Health Care Law Today
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management (e.g., Wegovy®) and are now being explored for treating a wide range of health conditions.
11 March 2025
Consumer Class Defense Counsel
No Harm, No Foul: Greenwashing Lawsuit Dismissed for Lack of Article III Standing
It is well-settled that under Article III of the Constitution, United States federal courts are limited to trying “cases and controversies.”